Athira Last Patient Completed Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s

 Reporting of Topline Results Targeted by End of Third Quarter 2024

Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October 29, 2024, in Madrid, Spain

Athira Pharma, Inc (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the completion of dosing for the last patient in the Phase 2/3 LIFT-AD clinical trial evaluating fosgonimeton in people with mild-to-moderate Alzheimer’s disease (AD). The Company is now targeting to report topline results from the LIFT-AD trial by the end of the third quarter of 2024 and has been invited to discuss the fuller data set during an oral presentation on October 29, 2024, at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place from October 29 – November 1, 2024, in Madrid, Spain.

https://www.globenewswire.com/news-release/2024/07/09/2910213/0/en/Athira-Pharma-Announces-Last-Patient-Completed-LIFT-AD-Clinical-Trial-of-Fosgonimeton-in-Mild-to-Moderate-Alzheimer-s-Disease.html